MSU
DMAA

Mizuho Securities USA’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Mizuho Securities USA’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9M Buy
2,069,605
+69,605
+3% +$737K 0.35% 42
2026
Q1 		$20.9M Buy
2,000,000
+566,517
+40% +$5.92M 0.49% 27
2025
Q4 		$14.8M Buy
1,433,483
+333,036
+30% +$3.44M 0.24% 57
2025
Q3 		$11.3M Buy
1,100,447
+180,660
+20% +$1.85M 0.23% 77
2025
Q2 		$9.29M Buy
919,787
+376,825
+69% +$3.81M 0.2% 98
2025
Q1 		$5.4M Buy
+542,962
New +$5.43M 0.12% 185

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.69% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.69% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.5% 1-Year Est. Return
SAMU
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
RC
RLH Capital Great Neck, New York $209M AUM

Mizuho Securities USA's DMAA Position: Q2 2026 in Review

Mizuho Securities USA increased its Drugs Made In America Acquisition Corp (DMAA) stake by 3.5% in Q2 2026, buying an estimated $737K and bringing the position to 2,069,605 shares worth $21.9M. The position accounts for 0.35% of the portfolio, ranked #42.

Mizuho Securities USA first reported a position in DMAA in Q1 2025 and has held it in 6 quarters since. 18 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Mizuho Securities USA held 2,069,605 shares of Drugs Made In America Acquisition Corp worth $21.9M as of Q2 2026.
  • Mizuho Securities USA bought 69,605 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $737K.
  • Drugs Made In America Acquisition Corp made up 0.35% of Mizuho Securities USA's portfolio in Q2 2026, its #42 holding.
  • Mizuho Securities USA first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
  • 18 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Mizuho Securities USA's 13F filing for Q2 2026, filed 24 Jul 2026.